Organisation paid for research Program year 2025 Source: CMS Open Payments

Links Clinical Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$3,439,939

3,511 payments

Through program year 2025, Links Clinical Trials LLC is reported as receiving $3,439,939 in research payments, across 3,511 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$1,326,727	534
2024	Research	$519,341	120
2023	Research	$685,615	879
2022	Research	$908,257	1,978

Breakdown

Who paid Research payments · program years 2022–2025

ITI, Inc. $1,192,783 519 payments
Regeneron Pharmaceuticals, Inc. $1,033,303 2,845 payments
Genentech, Inc. $773,623 27 payments
AbbVie, Inc. $256,469 21 payments
Neurocrine Biosciences, Inc. $170,941 94 payments
Chiesi USA, Inc. $6,820 4 payments
Allergan Inc. $6,000 1 payment

Studies the money was for Research payments · program years 2022–2025

Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) $1,024,803 2,844 payments
Roche Cancer Screening Collection Study $773,623 27 payments
Iti-007-321 $590,640 216 payments
Iti-007-601 $394,381 230 payments
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder $211,098 16 payments
Iti-007-421 $207,762 73 payments
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia $170,941 94 payments
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder $23,490 2 payments
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder $18,822 2 payments
A Master Protocol of Randomized, Double-Blind, Placebo-Controlled, Phase 2 Studies of siRNA Gene Silencing for the Treatment of Non- Alcoholic Steatohepatitis (NASH) in Participants With Genetic Risk Factors $8,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.